Vázquez GLA, Hidalgo MC, Broche PY, Valdés MY

Language: Spanish
References: 15
Page: 825-833
PDF size: 404.97 Kb.

ABSTRACT

Background: multiple sclerosis modifying drugs are intended to reduce the frequency of relapses, delay the progression of disability, as well as the appearance of new lesions in the Central Nervous System.
Objective: to determine the early indicators of response to treatment with IFNb-1a.
Methods: Observational, analytical longitudinal prospective cohort study in patients diagnosed with multiple sclerosis. Two study cohorts were formed, each with 39 patients.
Results: the mean and standard deviation of the expanded disability status scale at 36 months was 2.37 ± 1.86 in the study group and 3.15 ± 2.1 in the control group. In the outbreaks of .13 ± .33 in the study group and in the control group of .41 ± .59. New lesions in T2 after the first 12 months of treatment was 0.90 ± 1.16 for the study group and 1 ± 1.10 for the control. Extended-scale progression of disability status, pretreatment annualized relapse rate, age of disease onset, time since disease progression, and gadolinium-enhancing lesions were significantly associated with the odds ratio of older Probability of non-progression for the study group with respect to the control group for the combined variable progression by extended disability status scale and relapses.
Conclusions: early indicators of response to treatment with interferon beta-1a were identified; that help assess the response to treatment early, which has a positive impact on the evolution of the disease.

REFERENCES

1. Mousavizadeh A, Dastoorpoor M, Naimi E, Dohrabpour K. Time-trend analysis and developing a forecasting model for the prevalence of multiple sclerosis in Kohgiluyeh and Boyer-Ahmad Province, southwest of Iran. Public Health[Internet]. 2018[citado 15/06/2021];154:[aprox. 9 p.].Disponible en: http://www.sciencedirect.com/science/article/pii/S0022510X150026951.

2. De Angelis F, John NA, Brownlee WJ. Disease-modifying therapies for multiple sclerosis. BMJ. 2018;363:k4674.

3. Piñol C. Análisis de coste-efectividad del interferón beta-1b en el tratamiento de pacientes con síndrome desmielinizante aislado indicativo de esclerosis múltiple en España. Neurología[Internet]. 2016[citado 19/10/2021];31(4):[aprox. 8 p.]. Disponible en: https://www.elsevier.es/es-revista-neurologia-295-articulo-analisis-coste-efectividad-del-interferon-beta-1b-S02134853150006633.

4. Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Interferon ß for multiple sclerosis. Cold Spring Harb Perspect Med[Internet]. 2018[citado 19/10/2021];8(11):[aprox. 20 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29311124/4.

5. Lucchetta RC, Tonin FS, Borba HHL, Leonart LP, Ferreira VL, Bonetti AF, et al. Disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. CNS Drugs[Internet]. 2018[citado 19/10/2021];32(9):[aprox. 13 p.] . Disponible en: http://link.springer.com/article/10.1007/s40263-018-0541-55. .

6. Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med. 2017;65(5):883-91.

7. Vázquez Gómez LA, Hidalgo Mesa C, Beltrán González BM, Broche-Pérez Y, Mederos-Herrera AM. Efectividad de una estrategia para el seguimiento multidisciplinario de pacientes con esclerosis múltiple. EDUMECENTRO[Internet]. 2021[citado 4/11/2021];13(4):[aprox. 8 p.]. Disponible en: http://www.revedumecentro.sld.cu/index.php/edumc/article/view/18877.

8. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73.

9. Río J, Rovira A, Blanco Y, Sainz A, Perkal H, Robles R, et al. Respuesta al tratamiento con interferón beta en pacientes con esclerosis múltiple. Validación del Rio Score. Rev Neurol[Internet]. 2016[citado 19/10/2021];63(4):[aprox. 5 p.]. Disponible en: http://dialnet.unirioja.es/servlet/articulo?codigo=56272709.

10. Sormani MP, Rio J, Tintore M, Signori A, Li D, Cornelisse P, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler J[Internet]. 2013[citado 19/10/2021];19(5):[aprox. 7 p.]. Disponible en: http://journals.sagepub.com/doi/abs/10.1177/135245851246060510. .

11. Dobson R, Rudick RA, Turner B, Schmierer K, Giovannoni G. Assessing treatment response to interferon-ß: Is there a role for MRI? Neurology[Internet]. 2014[citado 19/10/2021];82(3):[aprox. 7 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902760/pdf/NEUROLOGY2013531699.pdf11. .

12. Trojano M, Tintore M, Montalban X, Hillert J, Kalincik T, Iaffaldano P, et al. Treatment decisions in multiple sclerosis-insights from real-world observational studies. Nat Rev Neurol[Internet]. 2017[citado 19/10/2021];13(2):[aprox. 13 p. ]. Disponible en: http://www.nature.com/articles/nrneurol.2016.18812.

13. Comi G, De Stefano N, Freedman MS, Barkhof F, Uitdehaag BM, de Vos M, et al. Subcutaneous interferon ß-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. J Neurol Neurosurg Psychiatry. 2017;88(4):285-94.

14. Uher T, Havrdova E, Sobisek L, Krasensky J, Vaneckova M, Seidl Z, et al. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up? Mult Scler J[Internet]. 2017[citado 19/10/2021];23(2):[aprox. 10 p.]. Disponible en: http://journals.sagepub.com/doi/abs/10.1177/135245851665052514.

15. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J[Internet]. 2018[citado 19/10/2021];24(2):[aprox. 25 p. ]. Disponible en: http://journals.sagepub.com/doi/abs/10.1177/135245851775104915.